Additional gold sales reported from Santa Elena project
Mar 19, 2018 07:02 am UTC| Business
CABORCA, Mexico, March 19, 2018 -- Mexus Gold US (OTCQB:MXSG)(“Mexus” or the “Company”) announced that its partner at the Santa Elena project has reported the sale of gold bearing activated carbon as a result of ongoing...
Hecla to Acquire Three High-Grade Nevada Gold Mines With the Acquisition of Klondex Mines Ltd.
Mar 19, 2018 07:01 am UTC| Business
COEUR D’ALENE, Idaho and VANCOUVER, British Columbia, March 19, 2018 -- Hecla Mining Company (NYSE:HL) (Hecla) and Klondex Mines Ltd. (NYSE American:KLDX) (TSX:KDX) (Klondex) today announced Hecla will acquire all the...
Azalead Announces First GDPR compliant Account-Based Marketing Platform for Global Manufacturers
Mar 19, 2018 07:00 am UTC| Business
PARIS, March 19, 2018 -- Azalead, the ABM platform for Global Manufacturers, has addressed the imminent new data privacy regulations that go into effect in May 2018. The General Data Protection Regulation (GDPR) is a...
Mar 19, 2018 07:00 am UTC| Business
Estimated Q4 2017 Gross Profit Rose 50%, on 29% Revenue Increase Forecasted Q4 2017 Highlights: Q4 2017 revenue growth of 29% to $59.5 million Q4 2017 gross profit improved by 50% to $11.9 millionQ4 2017 gross margin...
Motif Bio to present at upcoming investor and scientific conferences
Mar 19, 2018 07:00 am UTC| Business
NEW YORK, March 19, 2018 -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at the following...
Surgical Glue Market to Reach $6,936.5 Million by 2023: P&S Market Research
Mar 19, 2018 06:19 am UTC| Business
NEW YORK, March 19, 2018 -- According to the research report published by PS Market Research, global surgical glue market is projected to reach $6,936.5 million by 2023, the market growth is mainly driven by the rise in...
VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
Mar 19, 2018 06:01 am UTC| Business
Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15 Phase I study (VLA15-101) primary endpoint met No safety concerns associated with VLA15 in any treatment group ...